101
|
Dyduch G, Tyrak KE, Glajcar A, Szpor J, Okoń K. CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma. Postepy Dermatol Alergol 2017; 34:233-239. [PMID: 28670252 PMCID: PMC5471378 DOI: 10.5114/ada.2017.67845] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Accepted: 04/22/2016] [Indexed: 12/12/2022] Open
Abstract
INTRODUCTION Dendritic cells are crucial for cutaneous immune response. Their role in melanoma progression is however a matter of controversy. MATERIAL AND METHODS The number of dendritic cells within epidermis and in peri- and intratumoral location was analyzed using CD207 immunostain in 17 cases of in situ and 25 case of invasive melanoma. RESULTS Average peritumoral CD207+ cells count was 22.88 for all cases, 17.94 for in situ lesions and 26.24 for invasive cases. Average epidermal CD207+ cells count was 164.47 for all cases, 183.00 for in situ lesions and 150.78 - for invasive cases. In case of invasive melanomas, peritumoral CD207+ cells count was positively correlated with Breslow stage (R = 0.59) mitotic activity within the tumor (R = 0.62). Invasive cases with regression showed higher intratumoral and epidermal CD207+ cells count than the ones without (275.00 vs. 95.32 and 173.20 vs. 148.35) but lower peritumoral CD207+ cells count (17.60 vs. 27.26). Invasive cases with ulceration showed higher intratumoral and peritumoral CD207+ cells count than the ones without ulceration (220.08 vs. 55.67 and 44.17 vs. 9.69). CONCLUSIONS CD207+ cells play a role in both progression and regression of melanoma but their exact role needs further studies.
Collapse
Affiliation(s)
- Grzegorz Dyduch
- Chair of Pathomorphology, Jagiellonian University Medical College, Krakow, Poland
| | - Katarzyna E Tyrak
- II Chair of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland
| | - Anna Glajcar
- Chair of Pathomorphology, Jagiellonian University Medical College, Krakow, Poland
| | - Joanna Szpor
- Chair of Pathomorphology, Jagiellonian University Medical College, Krakow, Poland
| | - Krzysztof Okoń
- Chair of Pathomorphology, Jagiellonian University Medical College, Krakow, Poland
| |
Collapse
|
102
|
Dvořánková B, Szabo P, Kodet O, Strnad H, Kolář M, Lacina L, Krejčí E, Naňka O, Šedo A, Smetana K. Intercellular crosstalk in human malignant melanoma. PROTOPLASMA 2017; 254:1143-1150. [PMID: 27807664 DOI: 10.1007/s00709-016-1038-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Accepted: 10/19/2016] [Indexed: 06/06/2023]
Abstract
Incidence of malignant melanoma is increasing globally. While the initial stages of tumors can be easily treated by a simple surgery, the therapy of advanced stages is rather limited. Melanoma cells spread rapidly through the body of a patient to form multiple metastases. Consequently, the survival rate is poor. Therefore, emphasis in melanoma research is given on early diagnosis and development of novel and more potent therapeutic options. The malignant melanoma is arising from melanocytes, cells protecting mitotically active keratinocytes against damage caused by UV light irradiation. The melanocytes originate in the neural crest and consequently migrate to the epidermis. The relationship between the melanoma cells, the melanocytes, and neural crest stem cells manifests when the melanoma cells are implanted to an early embryo: they use similar migratory routes as the normal neural crest cells. Moreover, malignant potential of these melanoma cells is overdriven in this experimental model, probably due to microenvironmental reprogramming. This observation demonstrates the crucial role of the microenvironment in melanoma biology. Indeed, malignant tumors in general represent complex ecosystems, where multiple cell types influence the growth of genetically mutated cancer cells. This concept is directly applicable to the malignant melanoma. Our review article focuses on possible strategies to modify the intercellular crosstalk in melanoma that can be employed for therapeutic purposes.
Collapse
Affiliation(s)
- Barbora Dvořánková
- Institute of Anatomy, Charles University, 1st Faculty of Medicine, U Nemocnice 3, 128 00, Prague, Czech Republic
- BIOCEV, Průmyslová 595, 252 50, Vestec, Czech Republic
| | - Pavol Szabo
- Institute of Anatomy, Charles University, 1st Faculty of Medicine, U Nemocnice 3, 128 00, Prague, Czech Republic
- BIOCEV, Průmyslová 595, 252 50, Vestec, Czech Republic
| | - Ondřej Kodet
- Institute of Anatomy, Charles University, 1st Faculty of Medicine, U Nemocnice 3, 128 00, Prague, Czech Republic
- BIOCEV, Průmyslová 595, 252 50, Vestec, Czech Republic
- Department of Dermatology and Venerology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic
| | - Hynek Strnad
- Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 1083, 142 20, Prague, Czech Republic
| | - Michal Kolář
- Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 1083, 142 20, Prague, Czech Republic
| | - Lukáš Lacina
- Institute of Anatomy, Charles University, 1st Faculty of Medicine, U Nemocnice 3, 128 00, Prague, Czech Republic
- Department of Dermatology and Venerology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic
| | - Eliška Krejčí
- Institute of Anatomy, Charles University, 1st Faculty of Medicine, U Nemocnice 3, 128 00, Prague, Czech Republic
| | - Ondřej Naňka
- Institute of Anatomy, Charles University, 1st Faculty of Medicine, U Nemocnice 3, 128 00, Prague, Czech Republic
| | - Aleksi Šedo
- Institute of Biochemistry and Experimental Oncology, Charles University, 1st Faculty of Medicine, U Nemocnice 5, 128 53, Prague, Czech Republic
| | - Karel Smetana
- Institute of Anatomy, Charles University, 1st Faculty of Medicine, U Nemocnice 3, 128 00, Prague, Czech Republic.
- BIOCEV, Průmyslová 595, 252 50, Vestec, Czech Republic.
| |
Collapse
|
103
|
Massari NA, Nicoud MB, Sambuco L, Cricco GP, Lamas DJM, Ducloux MVH, Blanco H, Rivera ES, Medina VA. Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation. Oncotarget 2017; 8:26471-26491. [PMID: 28460440 PMCID: PMC5432273 DOI: 10.18632/oncotarget.15594] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 02/06/2017] [Indexed: 01/16/2023] Open
Abstract
The aims of the work were to improve our knowledge of the role of H4R in melanoma proliferation and assess in vivo the therapeutic efficacy of histamine, clozapine and JNJ28610244, an H4R agonist, in a preclinical metastatic model of melanoma. Additionally, we aimed to investigate the combinatorial effect of histamine and gamma radiation on the radiobiological response of melanoma cells.Results indicate that 1205Lu metastatic melanoma cells express H4R and that histamine inhibits proliferation, in part through the stimulation of the H4R, and induces cell senescence and melanogenesis. Daily treatment with H4R agonists (1 mg/kg, sc) exhibited a significant in vivo antitumor effect and importantly, compounds reduced metastatic potential, particularly in the group treated with JNJ28610244, the H4R agonist with higher specificity. H4R is expressed in benign and malignant lesions of melanocytic lineage, highlighting the potential clinical use of histamine and H4R agonists. In addition, histamine increased radiosensitivity of melanoma cells in vitro and in vivo. We conclude that stimulation of H4R by specific ligands may represent a novel therapeutic strategy in those tumors that express this receptor. Furthermore, through increasing radiation-induced response, histamine could improve cancer radiotherapy for the treatment of melanoma.
Collapse
Affiliation(s)
- Noelia A. Massari
- Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
- Immunology Department, School of Natural Sciences, National University of Patagonia San Juan Bosco, Chubut, Argentina
| | - Melisa B. Nicoud
- Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
- Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
| | | | - Graciela P. Cricco
- Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
| | - Diego J. Martinel Lamas
- Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
- Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
| | - María V. Herrero Ducloux
- Pathology Department, School of Natural Sciences, National University of Patagonia San Juan Bosco, Chubut, Argentina
| | - Horacio Blanco
- Hospital Municipal de Oncología “Marie Curie”, Buenos Aires, Argentina
| | - Elena S. Rivera
- Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
| | - Vanina A. Medina
- Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
- Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
| |
Collapse
|
104
|
Bosisio FM, van den Oord JJ. Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Arch 2017; 470:357-369. [PMID: 28054151 DOI: 10.1007/s00428-016-2058-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 12/03/2016] [Accepted: 12/19/2016] [Indexed: 12/18/2022]
Affiliation(s)
- Francesca Maria Bosisio
- Laboratory of Translational Cell and Tissue Research, KUL, Minderbroederstraat 19, 3000, Leuven, Belgium.
- Università degli studi di Milano-Bicocca, Milan, Italy.
| | - Joost J van den Oord
- Laboratory of Translational Cell and Tissue Research, KUL, Minderbroederstraat 19, 3000, Leuven, Belgium
| |
Collapse
|
105
|
Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count. BIOMED RESEARCH INTERNATIONAL 2017; 2017:6803756. [PMID: 28331853 PMCID: PMC5346357 DOI: 10.1155/2017/6803756] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/18/2016] [Revised: 01/30/2017] [Accepted: 02/06/2017] [Indexed: 12/16/2022]
Abstract
Background. Dendritic cells could be involved in immune surveillance of highly immunogenic tumors such as melanoma. Their role in the progression melanocytic nevi to melanoma is however a matter of controversy. Methods. The number of dendritic cells within epidermis, in peritumoral zone, and within the lesion was counted on slides immunohistochemically stained for CD1a, CD1c, DC-LAMP, and DC-SIGN in 21 of dysplastic nevi, 27 in situ melanomas, and 21 invasive melanomas. Results. We found a significant difference in the density of intraepidermal CD1c+ cells between the examined lesions; the mean CD1c cell count was 7.00/mm2 for invasive melanomas, 2.94 for in situ melanomas, and 13.35 for dysplastic nevi. The differences between dysplastic nevi and melanoma in situ as well as between dysplastic nevi and invasive melanoma were significant. There was no correlation in number of positively stained cells between epidermis and dermis. We did not observe any intraepidermal DC-LAMP+ cells neither in melanoma in situ nor in invasive melanoma as well as any intraepidermal DC-SIGN+ cells in dysplastic nevi. Conclusion. It was shown that the number of dendritic cells differs between dysplastic nevi, in situ melanomas, and invasive melanomas. This could eventually suggest their participation in the development of melanoma.
Collapse
|
106
|
Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EHW, van den Berg JH, Haanen JBAG, Smit VTHBM, Oosting J, van der Burg SH, Verdegaal EME. Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. Cancer Immunol Res 2017; 5:170-179. [PMID: 28073773 DOI: 10.1158/2326-6066.cir-16-0288] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Revised: 12/09/2016] [Accepted: 12/11/2016] [Indexed: 11/16/2022]
Abstract
The presence of tumor-infiltrating immune cells is associated with longer survival and a better response to immunotherapy in early-stage melanoma, but a comprehensive study of the in situ immune microenvironment in stage IV melanoma has not been performed. We investigated the combined influence of a series of immune factors on survival and response to adoptive cell transfer (ACT) in stage IV melanoma patients. Metastases of 73 stage IV melanoma patients, 17 of which were treated with ACT, were studied with respect to the number and functional phenotype of lymphocytes and myeloid cells as well as for expression of galectins-1, -3, and -9. Single factors associated with better survival were identified using Kaplan-Meier curves and multivariate Cox regression analyses, and those factors were used for interaction analyses. The results were validated using The Cancer Genome Atlas database. We identified four parameters that were associated with a better survival: CD8+ T cells, galectin-9+ dendritic cells (DC)/DC-like macrophages, a high M1/M2 macrophage ratio, and the expression of galectin-3 by tumor cells. The presence of at least three of these parameters formed an independent positive prognostic factor for long-term survival. Patients displaying this four-parameter signature were found exclusively among patients responding to ACT and were the ones with sustained clinical benefit. Cancer Immunol Res; 5(2); 170-9. ©2017 AACR.
Collapse
Affiliation(s)
- Sara M Melief
- Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands
| | - Valeria V Visconti
- Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands
| | - Marten Visser
- Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands
| | - Merel van Diepen
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Ellen H W Kapiteijn
- Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands
| | - Joost H van den Berg
- Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - John B A G Haanen
- Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Vincent T H B M Smit
- Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands
| | - Jan Oosting
- Bioinformatics Center of Expertise, Leiden University Medical Center, Leiden, the Netherlands
| | - Sjoerd H van der Burg
- Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands
| | - Els M E Verdegaal
- Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
| |
Collapse
|
107
|
Vasaturo A, Di Blasio S, Verweij D, Blokx WAM, van Krieken JH, de Vries IJM, Figdor CG. Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. Histopathology 2016; 70:643-649. [PMID: 27571246 DOI: 10.1111/his.13070] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 08/26/2016] [Indexed: 12/12/2022]
Abstract
AIMS The quality and quantity of the infiltration of immune cells into tumour tissues have substantial impacts on patients' clinical outcomes, and are associated with response to immunotherapy. Therefore, the precise analysis of tumour-infiltrating lymphocytes (TILs) is becoming an important additional pathological biomarker. Analysis of TILs is usually performed semiquantitatively by pathologists on haematoxylin and eosin-stained or immunostained tissue sections. However, automated quantification outperforms semiquantitative approaches, and is becoming the standard. Owing to the presence of melanin pigment, this approach is seriously hampered in melanoma, because the spectrum of melanin lies close to that of commonly used immunohistochemical stains. Aim of this study is to overcome the technical issues due to the presence of melanin for an automated and accurate quantification of TILs in melanoma. METHODS AND RESULTS Here, we successfully applied a novel multispectral imaging (MSI) technique to enumerate T cells in human primary melanomas. This microscopy technique combines imaging with spectroscopy to obtain both quantitative expression data and the tissue distributions of different cellular markers. We demonstrate that MSI allows complete and accurate analysis of TILs, successfully avoiding the blurring of images by melanin pigments, in whole tissue slide primary melanoma lesions, which could otherwise not be accurately detected by conventional digital image methodologies. CONCLUSIONS Our study highlights the potential of MSI for accurate assessment of immune cell infiltrates, including those in notoriously difficult tissues, such as pigmented melanomas. Quantification of tumour infiltration by different immune cell types is crucial in the search for new biomarkers to predict patient responses to immunotherapies. Our findings show that this innovative microscopy technique is an important extension of the armamentarium of pathologists.
Collapse
Affiliation(s)
- Angela Vasaturo
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
| | - Stefania Di Blasio
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
| | - Dagmar Verweij
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.,Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands
| | - Willeke A M Blokx
- Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands
| | - J Han van Krieken
- Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands
| | - I Jolanda M de Vries
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.,Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Carl G Figdor
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
| |
Collapse
|
108
|
Scali E, Mignogna C, Di Vito A, Presta I, Camastra C, Donato G, Bottoni U. Inflammation and macrophage polarization in cutaneous melanoma: Histopathological and immunohistochemical study. Int J Immunopathol Pharmacol 2016; 29:715-719. [PMID: 27387897 PMCID: PMC5806828 DOI: 10.1177/0394632016650895] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2015] [Accepted: 04/26/2016] [Indexed: 01/13/2023] Open
Abstract
Tumor-associated macrophages (TAMs) are considered to affect tumor growth and progression. Macrophages can be classified into two states of polarized activation, namely classically activated M1 macrophages and alternatively activated M2 macrophages. The dynamic balance between TAMs and tumor cells has an important impact on tumor homeostasis and progression. The aim of this study was to characterize the phenotype of TAMs present in different subtypes of superficial spreading cutaneous melanoma and their relationship with the lymphocytic infiltrate in order to identify new histopathological tools for melanoma prognosis and suitable targets for melanoma therapy. We selected four groups of patients with malignant melanoma in order to analyze the profile of polarized macrophage activation using immunohistochemical methods. Histopathological analysis showed that the macrophage polarization state appears to be more related to the lymphocytic infiltrate than to the thickness of the lesions. Further studies are necessary to increase understanding of the immunopathological dynamic of melanoma that may be modulated by future targeted immunotherapies.
Collapse
Affiliation(s)
- Elisabetta Scali
- Department of Health Sciences, University of Catanzaro "Magna Græcia", Catanzaro, Italy
| | - Chiara Mignogna
- Department of Health Sciences, University of Catanzaro "Magna Græcia", Catanzaro, Italy
| | - Anna Di Vito
- Clinical and Experimental Medicine Department, University of Catanzaro "Magna Græcia", Catanzaro, Italy
| | - Ivan Presta
- Department of Health Sciences, University of Catanzaro "Magna Græcia", Catanzaro, Italy
| | - Caterina Camastra
- Department of Health Sciences, University of Catanzaro "Magna Græcia", Catanzaro, Italy
| | - Giuseppe Donato
- Department of Health Sciences, University of Catanzaro "Magna Græcia", Catanzaro, Italy
| | - Ugo Bottoni
- Department of Health Sciences, University of Catanzaro "Magna Græcia", Catanzaro, Italy
| |
Collapse
|
109
|
Demirsoy S, Martin S, Maes H, Agostinis P. Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma. Front Oncol 2016; 6:240. [PMID: 27896217 PMCID: PMC5108812 DOI: 10.3389/fonc.2016.00240] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 10/27/2016] [Indexed: 12/21/2022] Open
Abstract
Melanoma has emerged as a paradigm of a highly aggressive and plastic cancer, capable to co-opt the tumor stroma in order to adapt to the hostile microenvironment, suppress immunosurveillance mechanisms, and disseminate. In particular, oncogene- and aneuploidy-driven dysregulations of proteostasis in melanoma cells impose a rewiring of central proteostatic processes, such as the heat shock and unfolded protein responses, autophagy, and the endo-lysosomal system, to avoid proteotoxicity. Research over the past decade has indicated that alterations in key nodes of these proteostasis pathways act in conjunction with crucial oncogenic drivers to increase intrinsic adaptations of melanoma cells against proteotoxic stress, modulate the high metabolic demand of these cancer cells and the interface with other stromal cells, through the heightened release of soluble factors or exosomes. Here, we overview and discuss how key proteostasis pathways and vesicular trafficking mechanisms are turned into vital conduits of melanoma progression, by supporting cancer cell's adaptation to the microenvironment, limiting or modulating the ability to respond to therapy and fueling melanoma dissemination.
Collapse
Affiliation(s)
- Seyma Demirsoy
- Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine, KU Leuven , Leuven , Belgium
| | - Shaun Martin
- Laboratory for Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven , Leuven , Belgium
| | - Hannelore Maes
- Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine, KU Leuven , Leuven , Belgium
| | - Patrizia Agostinis
- Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine, KU Leuven , Leuven , Belgium
| |
Collapse
|
110
|
Saul L, Ilieva KM, Bax HJ, Karagiannis P, Correa I, Rodriguez-Hernandez I, Josephs DH, Tosi I, Egbuniwe IU, Lombardi S, Crescioli S, Hobbs C, Villanova F, Cheung A, Geh JLC, Healy C, Harries M, Sanz-Moreno V, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN. IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Sci Rep 2016; 6:29736. [PMID: 27411958 PMCID: PMC4944184 DOI: 10.1038/srep29736] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 06/22/2016] [Indexed: 12/19/2022] Open
Abstract
B cells participate in immune surveillance in human circulation and tissues, including tumors such as melanoma. By contrast, the role of humoral responses in cutaneous immunity is underappreciated. We report circulating skin-homing CD22+CLA+B cells in healthy volunteers and melanoma patients (n = 73) and CD22+ cells in melanoma and normal skin samples (n = 189). Normal and malignant skin featured mature IgG and CD22 mRNA, alongside mRNA for the transiently-expressed enzyme Activation-induced cytidine Deaminase (AID). Gene expression analyses of publically-available data (n = 234 GEO, n = 384 TCGA) confirmed heightened humoral responses (CD20, CD22, AID) in melanoma. Analyses of 51 melanoma-associated and 29 normal skin-derived IgG sequence repertoires revealed lower IgG1/IgGtotal representation compared with antibodies from circulating B cells. Consistent with AID, comparable somatic hypermutation frequencies and class-switching indicated affinity-matured antibodies in normal and malignant skin. A melanoma-associated antibody subset featured shorter complementarity-determining (CDR3) regions relative to those from circulating B cells. Clonal amplification in melanoma-associated antibodies and homology modeling indicated differential potential antigen recognition profiles between normal skin and melanoma sequences, suggesting distinct antibody repertoires. Evidence for IgG-expressing B cells, class switching and antibody maturation in normal and malignant skin and clonally-expanded antibodies in melanoma, support the involvement of mature B cells in cutaneous immunity.
Collapse
Affiliation(s)
- Louise Saul
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom.,Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, 3rd Floor Bermondsey Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom
| | - Kristina M Ilieva
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom.,Breast Cancer Now Research Unit, Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, 3rd Floor Bermondsey Wing, Guy's Hospital, London, United Kingdom
| | - Heather J Bax
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom.,Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, 3rd Floor Bermondsey Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom
| | - Panagiotis Karagiannis
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| | - Isabel Correa
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| | - Irene Rodriguez-Hernandez
- Tumour Plasticity Laboratory, Randall Division of Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, United Kingdom
| | - Debra H Josephs
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom.,Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, 3rd Floor Bermondsey Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom
| | - Isabella Tosi
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| | - Isioma U Egbuniwe
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| | - Sara Lombardi
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom.,Skin Tumor Unit, St. John's Institute of Dermatology, Guy's Hospital, King's College London and Guy's and St Thomas' NHS Trust, London, United Kingdom
| | - Silvia Crescioli
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| | - Carl Hobbs
- Wolfson Center for Age-Related Diseases; King's College London, London, UK
| | - Federica Villanova
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| | - Anthony Cheung
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom.,Breast Cancer Now Research Unit, Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, 3rd Floor Bermondsey Wing, Guy's Hospital, London, United Kingdom
| | - Jenny L C Geh
- Department of Plastic Surgery at Guy's, King's, and St. Thomas' Hospitals, London, United Kingdom
| | - Ciaran Healy
- Department of Plastic Surgery at Guy's, King's, and St. Thomas' Hospitals, London, United Kingdom
| | - Mark Harries
- Clinical Oncology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Victoria Sanz-Moreno
- Tumour Plasticity Laboratory, Randall Division of Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, United Kingdom
| | - David J Fear
- Division of Asthma, Allergy and Lung Biology, Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma, Faculty of Life Sciences and Medicine, King's College London, Guy's Campus, London, United Kingdom
| | - James F Spicer
- Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, 3rd Floor Bermondsey Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom
| | - Katie E Lacy
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom.,Skin Tumor Unit, St. John's Institute of Dermatology, Guy's Hospital, King's College London and Guy's and St Thomas' NHS Trust, London, United Kingdom
| | - Frank O Nestle
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| | - Sophia N Karagiannis
- St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London SE1 9RT, United Kingdom
| |
Collapse
|
111
|
Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D. Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Rev Clin Immunol 2016; 12:879-93. [PMID: 27070898 DOI: 10.1080/1744666x.2016.1176529] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
When malignant melanoma is diagnosed early, surgical resection is the intervention of choice and is often curative, but many patients present with unresectable disease at later stages. Due to its complex etiology paired with well-documented chemoresistance and high metastatic potential, patients with advanced melanoma had a poor prognosis, and the treatment of this disease remained unsatisfactory for many years. Recently, targeted therapy, immune checkpoint inhibition, or combinatory approaches have revolutionized the therapeutic options of melanoma allowing considerable improvement in disease control and survival. In this review we will summarize these novel therapeutic strategies with particular focus on combinatory immunotherapies and further discuss recent data derived from immunogenomic studies and potential options to improve the therapeutic efficacy of immune modulatory approaches.
Collapse
Affiliation(s)
- Andrea Guennoun
- a Division of Translational Medicine , Research Branch, Sidra Medical and Research Center , Doha , Qatar
| | - Heba Sidahmed
- a Division of Translational Medicine , Research Branch, Sidra Medical and Research Center , Doha , Qatar
| | - Cristina Maccalli
- b Tumor Biology, Immunology and Therapy Section, Division of Translational Medicine , Research Branch, Sidra Medical and Research Center , Doha , Qatar
| | - Barbara Seliger
- c Institute of Medical Immunology , Martin Luther University Halle-Wittenberg , Halle , Germany
| | - Francesco M Marincola
- d Office of the Chief Research Officer (CRO) , Research Branch, Sidra Medical and Research Center , Doha , Qatar
| | - Davide Bedognetti
- b Tumor Biology, Immunology and Therapy Section, Division of Translational Medicine , Research Branch, Sidra Medical and Research Center , Doha , Qatar
| |
Collapse
|
112
|
van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 2016; 16:219-33. [PMID: 26965076 DOI: 10.1038/nrc.2016.16] [Citation(s) in RCA: 494] [Impact Index Per Article: 61.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease, carcinoma in situ or minimal residual disease, therapeutic vaccination can be clinically successful as monotherapy; however, in established cancers, therapeutic vaccines will require co-treatments to overcome immune evasion and to become fully effective. In this Review, we discuss the progress that has been made in overcoming immune evasion controlled by tumour cell-intrinsic factors and the tumour microenvironment. We summarize how therapeutic benefit can be maximized in patients with established cancers by improving vaccine design and by using vaccines to increase the effects of standard chemotherapies, to establish and/or maintain tumour-specific T cells that are re-energized by checkpoint blockade and other therapies, and to sustain the antitumour response of adoptively transferred T cells.
Collapse
Affiliation(s)
| | - Ramon Arens
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Ferry Ossendorp
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | | | - Cornelis J M Melief
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
- ISA Pharmaceuticals, J. H. Oortweg 19, 2333 CH, Leiden, The Netherlands
| |
Collapse
|
113
|
Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx WA, Massi D, Thompson JF, Scolyer RA, van Baren N, van den Oord JJ. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol 2016; 29:347-58. [PMID: 26867783 DOI: 10.1038/modpathol.2016.28] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Revised: 11/13/2015] [Accepted: 12/21/2015] [Indexed: 12/20/2022]
Abstract
Melanoma is not only one of the most immunogenic cancers but also one of the most effective cancers at subverting host immunity. The role of T lymphocytes in tumor immunity has been extensively studied in melanoma, whereas less is known about the importance of B lymphocytes. The effects of plasma cells (PCs), in particular, are still obscure. The aim of this study was to characterize pathological features and clinical outcome of primary cutaneous melanomas associated with PCs. Moreover, we investigated the origins of the melanoma-associated PCs. Finally, we studied the outcome of patients with primary melanomas with PCs. We reviewed 710 melanomas to correlate the presence of PCs with histological prognostic markers. Immunohistochemistry for CD138 and heavy and light chains was performed in primary melanomas (PM) and in loco-regional lymph nodes (LN), both metastatic and not metastatic. In three PM and nine LN with frozen material, VDJ-rearrangement was analyzed by Gene Scan Analysis. Survival analysis was performed on a group of 85 primary melanomas >2 mm in thickness. Forty-one cases (3.7%) showed clusters/sheets of PCs. PC-rich melanomas occurred at an older age and were thicker, more often ulcerated and more mitotically active (P<0.05). PCs were polyclonal and often expressed IgA in addition to IgG. In LN, clusters/sheets of IgA+ PCs were found both in the sinuses and subcapsular areas. Analysis of VDJ-rearrangements showed the IgA to be oligoclonal. Melanomas with clusters/sheets of PCs had a significantly worse survival compared with melanomas without PCs while, interestingly, melanomas with sparse PCs were associated with a better clinical outcome (P=0.002). In conclusion, melanomas with sheets/clusters of PCs are associated with worse prognosis. IgG and IgA are the isotypes predominantly produced by these PCs. IgA oligoclonality suggests an antigen-driven response that facilitates melanoma progression by a hitherto unknown mechanism.
Collapse
Affiliation(s)
- Francesca M Bosisio
- Laboratory of Translational Cell and Tissue Research, University of Leuven, KUL, Leuven, Belgium.,Università Degli Studi di Milano-Bicocca, Milan, Italy
| | - James S Wilmott
- Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
| | - Nathalie Volders
- Laboratory of Translational Cell and Tissue Research, University of Leuven, KUL, Leuven, Belgium
| | - Marjorie Mercier
- Ludwig Institute for Cancer Research and de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Jasper Wouters
- Laboratory of Translational Cell and Tissue Research, University of Leuven, KUL, Leuven, Belgium
| | - Marguerite Stas
- Department of Surgical Oncology, UZ Gasthuisberg and KU Leuven, Leuven, Belgium
| | | | - Daniela Massi
- Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | - John F Thompson
- Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
| | - Richard A Scolyer
- Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.,Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Nicolas van Baren
- Ludwig Institute for Cancer Research and de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Joost J van den Oord
- Laboratory of Translational Cell and Tissue Research, University of Leuven, KUL, Leuven, Belgium
| |
Collapse
|
114
|
Hartsough EJ, Aplin AE. Of Mice and Melanoma: PDX System for Modeling Personalized Medicine. Clin Cancer Res 2016; 22:1550-2. [PMID: 26842234 DOI: 10.1158/1078-0432.ccr-15-3054] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Accepted: 01/11/2016] [Indexed: 01/09/2023]
Abstract
Targeted therapies have advanced the treatment options for cutaneous melanoma, but many patients will progress on drug. Patient-derived xenografts (PDX) can be used to recapitulate therapy-resistant tumors. Furthermore, PDX modeling can be utilized in combination with targeted sequencing and phosphoproteomic platforms, providing preclinical basis for second-line targeted inhibitor strategies. See related article by Krepler et al., p. 1592.
Collapse
Affiliation(s)
- Edward J Hartsough
- Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Andrew E Aplin
- Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
| |
Collapse
|
115
|
Nguyen AH, Koenck C, Quirk SK, Lim VM, Mitkov MV, Trowbridge RM, Hunter WJ, Agrawal DK. Triggering Receptor Expressed on Myeloid Cells in Cutaneous Melanoma. Clin Transl Sci 2015; 8:441-4. [PMID: 26184544 DOI: 10.1111/cts.12308] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The tumor microenvironment plays an important role in the progression of melanoma, the prototypical immunologic cutaneous malignancy. The triggering receptor expressed on myeloid cells (TREM) family of innate immune receptors modulates inflammatory and innate immune signaling. It has been investigated in various neoplastic diseases, but not in melanoma. This study examines the expression of TREM-1 (a proinflammatory amplifier) and TREM-2 (an anti-inflammatory modulator and phagocytic promoter) in human cutaneous melanoma and surrounding tissue. Indirect immunofluorescence staining was performed on skin biopsies from 10 melanoma patients and staining intensity was semiquantitatively scored. Expression of TREM-1 and TREM-2 was higher in keratinocytes than melanoma tissue (TREM-1: p < 0.01; TREM-2: p < 0.01). Whereas TREM-2 was the dominant isoform expressed in normal keratinocytes, TREM-1 expression predominated in melanoma tissue (TREM-1 to TREM-2 ratio: keratinocytes = 0.78; melanoma = 2.08; p < 0.01). The increased TREM ratio in melanoma tissue could give rise to a proinflammatory and protumor state of the microenvironment. This evidence may be suggestive of a TREM-1/TREM-2 paradigm in which relative levels dictate inflammatory and immune states, rather than absolute expression of one or the other. Further investigation regarding this paradigm is warranted and could carry prognostic or therapeutic value in treatment for melanoma.
Collapse
Affiliation(s)
- Austin Huy Nguyen
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Carleigh Koenck
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Shannon K Quirk
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Victoria M Lim
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Mario V Mitkov
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Ryan M Trowbridge
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - William J Hunter
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Devendra K Agrawal
- Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| |
Collapse
|
116
|
Graziani G, Lacal PM. Neuropilin-1 as Therapeutic Target for Malignant Melanoma. Front Oncol 2015; 5:125. [PMID: 26090340 PMCID: PMC4453476 DOI: 10.3389/fonc.2015.00125] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Accepted: 05/19/2015] [Indexed: 01/13/2023] Open
Abstract
Neuropilin-1 (NRP-1) is a transmembrane glycoprotein that acts as a co-receptor for various members of the vascular endothelial growth factor (VEGF) family. Its ability to bind or modulate the activity of a number of other extracellular ligands, such as class 3 semaphorins, TGF-β, HGF, FGF, and PDGF, has suggested the involvement of NRP-1 in a variety of physiological and pathological processes. Actually, this co-receptor has been implicated in axon guidance, angiogenesis, and immune responses. NRP-1 is also expressed in a variety of cancers (prostate, lung, pancreatic, or colon carcinoma, melanoma, astrocytoma, glioblastoma, and neuroblastoma), suggesting a critical role in tumor progression. Moreover, a growing amount of evidence indicates that NRP-1 might display important functions independently of other VEGF receptors. In particular, in the absence of VEGFR-1/2, NRP-1 promotes melanoma invasiveness, through the activation of selected integrins, by stimulating VEGF-A and metalloproteinases secretion and modulating specific signal transduction pathways. This review is focused on the role of NRP-1 in melanoma aggressiveness and on the evidence supporting its use as target of therapies for metastatic melanoma.
Collapse
Affiliation(s)
- Grazia Graziani
- Department of Systems Medicine, University of Rome "Tor Vergata" , Rome , Italy
| | - Pedro M Lacal
- Laboratory of Molecular Oncology, "Istituto Dermopatico dell'Immacolata", Istituto di Ricovero e Cura a Carattere Scientifico , Rome , Italy
| |
Collapse
|